Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
APX-3330 by Opus Genetics for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to...
Data Insights
Phentolamine mesylate by Opus Genetics for Presbyopia: Likelihood of Approval
Phentolamine mesylate is under clinical development by Opus Genetics and currently in Phase III for Presbyopia. According to GlobalData, Phase...